J. Michael Pearson, CEO of Valeant Pharmaceuticals, will be taking a medical leave of absence after being hospitalized with a severe case of pneumonia. Pearson, 56, began his career with Valeant in 2008, after serving as head of global pharmaceutical practices for 23 years with consulting firm McKinsey & Co. Valeant released no further details about Pearson’s leave of absence, but announced three executives who will take over for him in the interim.
Robert Chai-Onn, 44, is the company’s general counsel and oversees corporate legal teams and activities. Chai-Onn joined Valeant in 2004.
Dr. Ari Kellen, 51, serves as Valeant’s executive VP and company group chairman. Kellen is responsible for U.S. dermatology, Bausch and Lomb and Valeant’s Latin American business. He joined the company in January 2014.
Robert Rosiello, 57, is the company’s executive VP and CFO. Before his appointment as CFO in July, he spent 30 years at McKinsey & Co., where he assisted healthcare companies with mergers and acquisitions.